Walshe V, Nash A, Barry M
National Centre for Pharmacoeconomics, St James Hospital, Dublin.
Ir Med J. 2006 May;99(5):144-5.
Cholesterol lowering statin therapy accounted for over 10% of total drug acquisition costs (87.5 million euros) under the Community Drugs Schemes in Ireland in 2004. Not surprisingly, the issue of value for money and cost effectiveness arises. Whilst statin therapy has proven cost effective in patients with established cardiovascular disease this is the first economic evaluation of statin therapy for primary prevention in the Irish healthcare setting. Using economic modelling techniques the incremental cost effectiveness of statin therapy in high risk individuals i.e. 10 year risk exceeding 15% ranged from 17,900 euros per life year gained (LYG) to 33,800 euros/LYG under the GMS scheme. Corresponding figures for the Drug Payment scheme were 24,500 euros/ LYG to 48,500 euros/LYG. All the statins could be considered cost effective i.e. threshold below 50,000 euros/LYG however atorvastatin proved the most cost effective statin in this pharmacoeconomic study.
2004年，在爱尔兰的社区药物计划下，降低胆固醇的他汀类药物疗法占药品采购总成本（8750万欧元）的10%以上。毫不奇怪，性价比和成本效益问题随之而来。虽然他汀类药物疗法已被证明对已确诊的心血管疾病患者具有成本效益，但这是首次在爱尔兰医疗环境中对他汀类药物疗法进行一级预防的经济评估。使用经济建模技术，他汀类药物疗法在高危个体（即10年风险超过15%）中的增量成本效益，在全科医疗服务计划（GMS）下，每获得一个生命年（LYG）的成本从17900欧元到33800欧元不等。药物支付计划的相应数字为每LYG 24500欧元至48500欧元。所有他汀类药物都可被认为具有成本效益，即阈值低于50000欧元/LYG，然而，在这项药物经济学研究中，阿托伐他汀被证明是最具成本效益的他汀类药物。
